Monday's Analysts' Upgrades, Downgrades

Change in Ratings

Alpha Natural(ANR Quote) downgraded at UBS to neutral rating from buy. However, price target and fiscal-year 2000 EPS estimates upped to $44 and $2.95, respectively.

Peabody(BTU Quote) downgraded at UBS to neutral rating from buy. However, price target and fiscal-year 2000 EPS estimates upped to $64 from $63 and $3.16 from $3.10, respectively.

Graco(GGG Quote) downgraded at Goldman to sell with a $32 price target. Stock has a lot of exposure to a U.S. slowdown and lacks near-term catalysts.

Hain Celestial(HAIN Quote) upgraded at UBS to buy rating from neutral. Price target holds at $35 while fiscal-year 2008 EPS dips to $1.65 from $1.70.

Marshall & Ilsley(MI Quote) downgraded at Goldman to neutral. Estimates also cut, as the company has high exposure to construction loans. $26 price target.

Motorola(MOT Quote) downgraded at Oppenheimer from outperform to perform. Checks suggest a large shortfall in handset demand this quarter. Stock is also losing sum-of-the-parts valuation support.

New York Times(NYT Quote) downgraded at Deutsche from hold to sell with a $15 price target. Estimates also cut, to reflect soft national advertising trends.

SPX(SPW Quote) downgraded at JPMorgan from overweight to neutral. Valuation call. Stock is up 20% since Jan. 10, and is already pricing in strong near-term earnings momentum.

Syntel(SYNT Quote) downgraded at Wachovia to market perform. 2008 estimates also cut below the consensus, as to reflect higher investment costs.

Yum! Brands(YUM Quote) upgraded at UBS to buy rating from neutral. Price target holds at $43 and fiscal-year 2008 EPS holds at $1.91.

Stock Comments/EPS Changes

Genentech(DNA Quote) estimates raised at Goldman through 2009. Avastin received approval for breast cancer about a year ahead of expectations, which should add about 4 cents a share to annual earnings. Buy rating and $42 price target.

Williams(WMB Quote) numbers raised at Morgan Stanley through 2009. Company to benefit from higher commodity prices and should see wider NGL margins. Overweight rating and new $47 price target.